Even at the J.P. Morgan Healthcare Conference, the tide seems to have turned. This year, there were at least eight events that I personally heard of that were women-only and overflowing.
Bio-Rad Laboratories has had a busy few weeks, launching a single-cell sequencing system with Illumina and acquiring a major competitor in the digital PCR space, RainDance Technologies. The activity positions the research tools provider for several trends on the horizon, including liquid biopsy.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
From too little genomic diversity to an overemphasis on rare diseases and oncology, here are three trends from the 35th J.P. Morgan Healthcare Conference that will continue to play out this year.
One key trend among startups was the emergence of second order companies attacking problems created by the increasing proliferation of digital health and connected medical devices.
Advocates of machine learning say radiology is undergoing a major transformation, but some are careful in not wanting to upset the apple cart too much.
As a panel discussion turned to the question of how much digital health data is too much, the senior vice president for digital health at the world's largest wearables manufacturer expressed concern that physicians would view taking on all that data as a liability risk.
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
Dr. J. Nwando Olayiwola will head up an office to anchor the company’s expansion in California to support Medicaid patients there.
The infamous LifeSci Advisor's reception at JPM16 may prove to be one of the best things to happen to women in biotech in recent years, serving as a catalyst for many powerful men and women to unite around the cause and to begin to take action.
Give a consumer a choice between a supersized bag of Doritos and a digital health product and they are going to ask you for the guacamole, not a charger.
One of the biggest biotech buzz fields in recent years, CAR-T immunotherapy is on the cusp of gaining an FDA approval. There is no precedent for what comes next. On Wednesday, we got an early glimpse as Kite Pharma outlined its commercialization plan in a packed presentation at #JPM17.
We will highlight Build My Health's revenue practice management tools, which could help physician practices add up to $250,000 to their practices.
Science 37 illustrated a way forward for pharma companies to improve clinical trial recruitment through social media and remote monitoring, reducing drug development costs.
Greg Simon who was at the J.P. Morgan Healthcare Conference to discuss the Cancer Moonshot criticized President-elect Trump's stance on pharma companies and exhorted the industry to respond rationally.
President-elect Trump unleashed on the drug industry in a Wednesday morning press conference, strongly criticizing international manufacturing practices and the lack of price negotiations at home.
One element of the program involves a fresh food pharmacy — an initiative that "prescribes" a food program for diabetic, food-insecure patients.
HealthX Ventures has hired Redox Engine's business development staffer.